An observational study in Hepatocellular Carcinoma, Transcatheter Arterial ChEmoembolization and Regorafenib, sponsored by WenBo Guo. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-13.
Sponsored by WenBo Guo · Observational
. 1 Clarify the difference in efficacy of regofinib combined with TACE compared with second-line treatment of advanced liver cancer; 2. To evaluate the safety and prognostic imaging factors of regorofenib in advanced second-line therapy; 3, to explore whether it is necessary to increase the treatment of TACE in the second-line treatment of advanced HCC.
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's planned enrollment of 192 is above the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →This is the only study on the registry with WenBo Guo as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients with hepatocellular carcinoma
( - ) After pathological / clinical diagnosis of hepatocellular carcinoma or radical resection of hepatocellular carcinoma; ( - ) CNLC Ⅲa Patients with intrahepatic recurrence before (including a); ( - ) Previous failure of first-line systemic treatment; ( - ) Age: 18-75 years old; ( - ) Child-Pugh 7 points; ( - ) ECOG PS Grade 0-2; ( - ) At least one measurable lesion in the liver.
Exclusion Criteria:
( - ) Known hepatobiliary tubular cell carcinoma and mixed cell carcinoma and fibrolamellar cell carcinoma; ( - ) Previous (within 5 years) or concurrent other incurable malignant tumors; ( - ) Having received local treatment, systemic chemotherapy, radiotherapy other than TACE during the first-line systemic treatment; ( - ) During the second-line systemic treatment, I also received local treatment, systemic chemotherapy, radiotherapy other than TACE; ( - ) Serious uncontrollable systemic and other systemic diseases, such as uremia, cardiovascular and cerebrovascular accidents; ( - ) Allergy to any drug included in the study; ( - ) Pregnant or lactating women;
Regorafenib + TACE
Procedure: TACE · Drug: Regorafenib
Regorafinib
Drug: Regorafenib
Transcatheter Arterial Chemoembolization
Regorafenib alone
Overall survival
defined as the time between the start of second-line treatment and the end of follow-up / death.
Time frame: 2022.12.27-2025.09.30
Progression-free survival for the first subsequent treatment PFS 2
defined as the time of second-line treatment initiation to the date of radiological progression or death from any cause.
Time frame: 2022.12.27-2025.09.30
Plan to share: No — Regorafenib Alone or in Combined with Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma after First Line Targeted Therapy
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.